Form 4: PETMED Director LaCamp Awarded Restricted Stock

PetMed Express Director James LaCamp received 34,866 restricted shares as part of the company's 2024 Omnibus Incentive Plan.

Summary

• James LaCamp, a Director of PetMed Express Inc. (PETS), was awarded 34,866 shares of common stock.
• The transaction occurred on October 30, 2025, and was an acquisition (A) of securities.
• The shares were granted as a restricted stock award under the PetMed Express, Inc. 2024 Omnibus Incentive Plan.
• Of the awarded shares, 1,020 shares will vest on October 19, 2026, and 33,846 shares will vest on October 30, 2026.
• Vesting is contingent upon Mr. LaCamp's continued service on the Board of Directors.
• Following this transaction, Mr. LaCamp beneficially owns 34,866 shares of common stock directly.

Sentiment

Score: 6

Explanation: Slightly positive, as it indicates continued commitment from a director and aligns interests, which is generally viewed favorably, though it's a routine compensation event.

Positives

• The restricted stock award aligns the director's financial interests with those of the shareholders, incentivizing long-term performance.
• The award is part of an approved incentive plan, indicating structured compensation practices.

Negatives

• The vesting of these shares will result in a minor dilution of existing shareholder equity, although this is a common practice for executive compensation.

Risks

• The vesting of the restricted stock is subject to James LaCamp's continued service on the Board of Directors, meaning the shares could be forfeited if service ceases before vesting dates.

Future Outlook

The restricted stock award provides a future incentive for Director James LaCamp to remain with PetMed Express and contribute to its long-term success, with vesting scheduled for October 2026.

Industry Context

Restricted stock awards are a common form of equity compensation for directors and executives across various industries, designed to align their interests with shareholders and promote long-term retention and performance.

Comparison to Industry Standards

• The use of restricted stock awards for director compensation is a standard practice in corporate governance, comparable to compensation structures seen in many publicly traded companies across the retail and healthcare sectors.
• The vesting schedule, typically over one to three years, is also consistent with industry norms for such awards, aiming to ensure continued service and performance.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor potential dilution upon vesting, but also benefit from aligned director incentives for long-term company performance.
• Director (James LaCamp): Receives equity compensation, providing a direct financial interest in the company's future success and incentivizing continued service.

Next Steps

• James LaCamp's continued service on the Board of Directors until the vesting dates of October 19, 2026, and October 30, 2026.

Key Dates

Keywords

PetMed Express, PETS, James LaCamp, Restricted Stock Award, Insider Transaction, Form 4, Director Compensation, Equity Incentive Plan